Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy.

ABSTRACT: Background: Significant changes in renal cell carcinoma (RCC) drug treatment and improved access to abdominal imaging have recently been implemented. The impact of these changes on patient characteristics and prognosis remains to be quantified. Methods: A population-based cohort of 210,418 RCC cases from the Centre for Cancer Registry Data (ZfKD) diagnosed in Germany between 2000 and 2019 was analyzed in this observational study. Three time periods of diagnosis were defined, the first (2000-2005) functioning as a control. The remaining were defined according to the introduction of tyrosine kinase targeting drugs (2006-2014) and checkpoint inhibitor drugs (2015-2019). Five-year relative survival (RS) trends for each risk group and metastatic RCC (mRCC) were determined using Po

SUBMITTER: Halfter K 

PROVIDER: S-EPMC12468357 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature